Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Wall Street stocks ended mixed on Thursday, lifted by Eli Lilly and Apple, as investors weighed progress in U.S. trade ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...

In an exclusive interview with NBC News' Stephanie Gosk, Eli Lilly's chief scientific officer says their weight loss pills ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, ...

A daily weight loss pill being tested by Eli Lilly could work as well as its GLP-1 injection counterparts like Ozempic, ...

It's Thursday morning, 11:50 a.m. ET -- and Eli Lilly (NYSE: LLY) stock is off to the races! This morning, the ...